Literature DB >> 28384939

Up the Duff With Non-Hodgkin's Lymphoma: The Traumas and the Dilemmas.

Sheeba Marwah1, Harsha Shailesh Gaikwad2, Ritin Mohindra3, Manjula Sharma4.   

Abstract

Lymphoma is fourth most frequent malignancy diagnosed prenatally (~1:6000 cases), with Hodgkin's Lymphoma (HL) forming the major chunk. However, in recent times, there has been an increase in occurrence of Non-Hodgkin's Lymphoma (NHL) due to late child bearing age and high incidence of AIDS-related NHL in developing countries. Managing NHL in pregnancy involves intricate medical, ethical and psychological issues. Diagnostic and treatment delays may influence the prognosis for indolent cases. Seen the complexity of the management decisions associated with NHL, interdisciplinary and individualized approach becomes imperative for each woman. We present a case of 25-year-old G2P0010 at 32 weeks Period of Gestation (PoG) with right sided deep cervical lymphadenopathy, who was diagnosed as aggressive malignant NHL and was subsequently started on chemotherapy after confirmation of diagnosis and eventually had an optimal feto-maternal outcome. The critical appraisal of the accessible data, identification of controversies and unresolved issues and proposal of elucidations about varied facets of NHL in pregnancy are also provided.

Entities:  

Keywords:  Chemotherapy; Fetus; Malformation; Pregnancy

Year:  2017        PMID: 28384939      PMCID: PMC5376804          DOI: 10.7860/JCDR/2017/23972.9221

Source DB:  PubMed          Journal:  J Clin Diagn Res        ISSN: 0973-709X


  15 in total

1.  Non-Hodgkin lymphoma in pregnancy presenting as acute liver failure.

Authors:  K S Stewart; M C Gordon
Journal:  Obstet Gynecol       Date:  1999-11       Impact factor: 7.661

2.  Non-Hodgkin's lymphoma presenting with gigantomastia in pregnancy.

Authors:  K W Windom; R S McDuffie
Journal:  Obstet Gynecol       Date:  1999-05       Impact factor: 7.661

Review 3.  Imaging of pregnant and lactating patients: part 2, evidence-based review and recommendations.

Authors:  Page I Wang; Suzanne T Chong; Ania Z Kielar; Aine M Kelly; Ursula D Knoepp; Michael B Mazza; Mitchell M Goodsitt
Journal:  AJR Am J Roentgenol       Date:  2012-04       Impact factor: 3.959

4.  Hematological malignancies and pregnancy: treat or no treat during first trimester.

Authors:  Agustin Avilés; Natividad Neri; María-Jesús Nambo
Journal:  Int J Cancer       Date:  2012-04-18       Impact factor: 7.396

Review 5.  Haematological cancers in pregnancy.

Authors:  Benjamin Brenner; Irit Avivi; Michael Lishner
Journal:  Lancet       Date:  2012-02-11       Impact factor: 79.321

Review 6.  Treatment of the pregnant mother with cancer: a systematic review on the use of cytotoxic, endocrine, targeted agents and immunotherapy during pregnancy. Part I: Solid tumors.

Authors:  Hatem A Azim; Fedro A Peccatori; Nicholas Pavlidis
Journal:  Cancer Treat Rev       Date:  2009-12-16       Impact factor: 12.111

Review 7.  The treatment of Hodgkin's and non-Hodgkin's lymphoma in pregnancy.

Authors:  David Pereg; Gideon Koren; Michael Lishner
Journal:  Haematologica       Date:  2007-08-01       Impact factor: 9.941

8.  Gonadotropin-releasing hormone agonist for the prevention of chemotherapy-induced ovarian failure in patients with lymphoma: 1-year follow-up of a prospective randomized trial.

Authors:  Isabelle Demeestere; Pauline Brice; Fedro A Peccatori; Alain Kentos; Isabelle Gaillard; Pierre Zachee; Rene-Olivier Casasnovas; Eric Van Den Neste; Julie Dechene; Vivianne De Maertelaer; Dominique Bron; Yvon Englert
Journal:  J Clin Oncol       Date:  2012-11-05       Impact factor: 44.544

9.  Delayed childbearing: more women are having their first child later in life.

Authors:  T J Matthews; Brady E Hamilton
Journal:  NCHS Data Brief       Date:  2009-08

10.  Cause-specific survival for women diagnosed with cancer during pregnancy or lactation: a registry-based cohort study.

Authors:  Hanne Stensheim; Bjørn Møller; Tini van Dijk; Sophie D Fosså
Journal:  J Clin Oncol       Date:  2008-11-24       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.